Aim: Many randomized controlled trials have been performed on the efficacy and mechanism of action of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on psoriasis. However, contradictory results have been obtained. This study wants to assess the effects of n-3 PUFAs on the severity of psoriasis.
INTRODUCTION
Psoriasis is a complex autoimmune inflammatory disease typically characterized by erythematous papules and plaques with silver scaling. Genetic predisposition plays a main role in the development of psoriasis; however, smoking, alcohol consumption, vitamin D deficiency, obesity and high body mass were also found to be associated in several studies. [1] [2] [3] Most cases are not severe enough to affect the patient's general health and are treated in the outpatient setting. Multiple treatment options are now available, including topical therapies, ultraviolet phototherapy and systemic therapies. Each treatment targets a different pathophysiology and spectrum of severity ranging from localized to systemic manifestation. The levels of arachidonic acid (AA) and its metabolites, particularly leukotriene B4 (LTB4) and 12-hydroxyeicosatetraenoic acid , are higher in psoriatic plaques than in clinically uninvolved skin. 4 Both LTB4 and 12-HETE are chemotactic for neutrophils. Therefore, during the last couple of decades, dietary fish oils (omega-3 polyunsaturated fatty acids [n-3 PUFAs]) have been used as an adjunct therapy because their anti-inflammatory and/or antichemotactic properties seem to induce a protective effect against cutaneous diseases, including psoriasis. 5 The n-3 PUFA family includes eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which modulate inflammatory responses by multiple mechanisms. 6 Based on these mechanisms, multiple randomized controlled trials have been conducted to show the clinical effectiveness of n-3 PUFAs. Although most of the results seemed promising, some have been contradictory. Therefore, we conducted a systematic review of all randomized controlled trials and observational studies that determined the effects of n-3 PUFAs on outcomes in patients with psoriasis compared with control treatment.
MATERIALS AND METHODS
This systematic review was conducted and reported according to the established guidelines for systematic review of randomized controlled trials and the Metaanalysis Of Observational Studies in Epidemiology statement [7] [8] [9] and was registered in PROSPERO (registration number: CRD42014013052).
Search strategy
Two study investigators (AS and SU) independently searched published studies indexed in the Cochrane Central Register of Controlled Trials (CENTRAL) of The Cochrane Library, PubMed/MEDLINE and EMBASE from database inception to November 2016. References of retrieved articles were also examined. The search terms used were 'psoriasis', 'fish oils', 'omega 3', 'EPA', 'DHA' and 'fatty acids'. Further details regarding the search terms and limits used for the literature search are included in the Appendix.
Inclusion and exclusion criteria
We included all published randomized clinical trials and prospective observational studies comparing n-3 PUFA treatment with control treatment in patients with psoriasis. Reviews, case reports, letters, commentaries and abstracts were not included because they could not be assessed for quality of study.
Participants
Studies that evaluated participants aged 18 years or older with any type of psoriasis (plaque, guttate, pustular, inverse, erythrodermic or psoriatic arthritis) were included.
Interventions
Studies that evaluated dietary or pharmacologic interventions using n-3 PUFAs such as EPA, DHA and dietary fish oils were included.
Comparisons
Studies that evaluated participants receiving either usual care or active placebo were included.
Outcome measures
The primary outcome was a comparison of psoriasis disease severity as measured by the Psoriasis Area Severity Index (PASI) score. The PASI is a tool used to measure the severity and extent of psoriasis by assessing the intensity (redness, thickness and scaling) and areas affected in four regions of the body: the head and neck, upper limbs, trunk, and lower limbs.
The secondary outcome measures were the Dermatology Life Quality Index (DLQI) score, visual analog scale (VAS) scores, percent total body surface area affected (%TBSA), and subjective reports of progression from clinicians or patients (e.g., itching, erythema, scaling, area involved, thickness and infiltration).
Data extraction and management
Two study investigators (AS and SU) independently reviewed the titles and abstracts of all identified citations. The inclusion criteria were independently applied to all identified studies. Only full-text articles written in English were included. Differing decisions were resolved by consensus.
Full-text versions of potentially relevant papers identified in the initial screening were retrieved. If multiple articles from the same study were found, only the article with the longest follow-up period was included. Data concerning study design, study duration, participant characteristics, interventions and outcome measures were independently extracted. We planned to contact the authors of the primary reports to request any unpublished data. If the authors did not reply, we planned to use only the available data for our analyses.
Assessment of bias risk
The methodological quality of each study was conducted by two authors (AS and SU) on the following items, in which each component was categorized as having high, low or unclear risk of bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting. Quality of observational study was evaluated using the Newcastle-Ottawa quality assessment scale which assessed each study in three areas: (i) the selection of the study groups; (ii) the comparability of the groups; and (iii) the ascertainment of the exposure or outcome of interest for case-control or cohort studies, respectively. 10 Discrepant opinions between authors were resolved by consensus.
RESULTS

Description of included studies
The initial search yielded 732 articles (Fig. 1) . A total of 720 articles were excluded because they were not randomized controlled trials or observational studies (427 articles), did not involve dietary or pharmacologic interventions with n-3 fatty acids (210 articles), did not perform a comparison (65 articles), or did not include the outcome of interest (18 articles). Eleven randomized controlled trials [4] [5] [6] [11] [12] [13] [14] [15] [16] [17] [18] and one open-label controlled observational study 19 were included, and the data of all 12 studies were extracted. The characteristics of the extracted studies are outlined in Table 1 .
Two studies 12, 15 reported criteria of psoriasis diagnosis. Different doses of EPA and DHA were tested in the intervention group, ranging from 0.216 to 5.400 g of EPA (median, 2.250 g; mean, 2.680 g; n = 10) and 0.132 to 4.200 g of DHA (median, 2.400 g; mean, 2.180 g; n = 7). The follow-up duration ranged from 10 days to 1 year (median, 11 weeks; mean, 105 days; n = 13). The effects of the n-3 PUFA doses and treatment durations varied among the 12 studies.
Six studies 4, [11] [12] [13] 16, 19 reported improvement in the patients' erythema, scaling, itching, area involved and infiltration. Gupta et al. 4 reported 35-48% improvement of patients' scaling, erythema, area involved and thickness, especially during concurrent n-3 PUFA and ultraviolet B (UVB) treatment but not in the placebo group. Grimminger et al.
11 is the only study that was conducted on hospitalized acute guttate psoriasis. They reported a significant improvement in all objective (erythema, infiltration, desquamation) and patients' subjective scoring system (appearance of lesions, impairment of daily life, pruritus, burn and pain) within 4-7 days after infusion of n-3 PUFA (P < 0.05); the exact numbers were not reported in the article. Guida et al.
12
reported > 50% reduction of PASI and > 70% reduction of DLQI at 6 months compared to the control group (P = 0.021 and P < 0.001, respectively). However there was no significant difference in VAS between intervention and control groups, with about 70-80% improvement in VAS in both groups. Bittiner et al. 13 reported significant improvement of itching (P < 0.05) and erythema (P < 0.05) while improvement of scaling and area involved did not meet statistical significance. Mayser et al. 16 reported significant improvement of PASI in both intervention and control groups compared to the baseline, in favor of then-3 PUFA group (P = 0.048). However, there was no difference in patients' own assessments (VAS) of psoriasis between the groups. One open-label, controlled observational study 19 reported 70% reduction in PASI (P < 0.0001), 78% reduction in DLQI (P < 0.0056) and 42% reduction in Nail Psoriasis Severity Index (NAPSI) (P < 0.048). The NAPSI is a scale to evaluate the severity of nail bed psoriasis and nail matrix psoriasis by area of involvement in the nail unit. 20 Furthermore, this study 19 also reported statistically significant improvement in all other parameters compared to the control group, including 80% improvement in pruritus, 61% improvement in erythema, 81% improvement in infiltration and 92% improvement in scaling.
Studies also reported reduced inflammatory markers in the intervention group. Grimminger et al. 11 measured the level of leukotriene B4 and B5, platelet-activating factor (PAF) and 5-HETE. They reported a steep increase in the generation of LTB5 and 5-HEPE starting from day 3 to day 10 of n-3 PUFA infusion, indicating the reduction of chemotactic and neutrophil activation. Mayser et al. 16 also found a more than 40-fold increase of LTB5, evidenced from day 3 to day 15, but there was only a slight decrease of chemotactic LTB4 in both intervention and control groups with no significant difference. However, Veale et al. 6 did not find any significant improvement by giving n-3 PUFA. LTB4 was found to have significantly decreased in the treatment group (P < 0.03) but not in the control group.
The other six studies 5, 6, 14, 15, 17, 18 reported no significant reduction in scaling, erythema, area involved or thickness. Gupta et al. 5 reported the mean time period elapsed before the psoriasis worsened to pre-therapy severity was 4.9 AE 0.5 weeks in the intervention group and 4.5 AE 0.6 weeks in the control group (P = 0.4). Veale et al. 6 reported no significant changes in articular index or skin itch at the end of the study, yet the subjects in the active treatment group had significantly more skin itch at the beginning (P = 0.03), thus suggesting the implementation of n-3 PUFA may be helpful for skin itch. Although Bjorneboe et al. 14 did not find any significant difference between both groups, the total n-3 PUFA in serum phospholipids was significantly increased as compared to pre-treatment values while causing a significant fall in the AA and linoleic acid content of serum phospholipids. Madland et al. 15 reported a significant improvement of joint pain in patients with psoriatic arthritis in both intervention and control groups; only improvement of joint swelling was noted in the intervention group. They also reported a significant rise in serum concentration of EPA and fall in the ratio of AA to EPA and n-3 to n-6 PUFA after treatment (P < 0.01). 15 Soyland et al. 17 reported a significant decrease in the infiltration and scaling scores (P < 0.01) in the intervention group, but also a significant decrease from baseline in the scores for desquamation (P < 0.05), redness (P < 0.05) and scaling (P < 0.01) in the control group; however, there were no significant differences between the two groups. Interestingly, Soyland's study also found that the concentration of EPA increased 3.6-fold, whereas DHA increased by 39% in serum phospholipids in subjects who received n-3 PUFA. In spite of that, there was no correlation between clinical response and the increased level of EPA (r = 0.069) or DHA (r = 0.021). Strong et al. 18 reported a very substantial improvement in intervention and control groups yet no significant difference between both groups. Details of outcome are presented in Table 2 . 
Risk of bias and quality assessment
The risk of bias in the included studies is summarized in Figure 2 . Only one study had selection bias. Two studies had performance bias. Three studies had attrition bias and reporting bias. One observational study 19 had selection bias. Overall, half of the included studies had low risk of bias and the other half had moderate risk of bias.
DISCUSSION Summary of main results
To the best of our knowledge, this is the first systematic review of the effects of n-3 PUFA intervention on the severity of psoriasis. Based on the results, whether n-3 PUFAs are effective in treating psoriasis remains controversial. Most studies included in this systematic review did not use the PASI score as the sole treatment outcome measurement. Of the seven studies that reported the PASI score, only one 12 reported an improvement in quality of life (QoL). Three studies reported either no difference in the subjective skin-itch VAS score 6, 16 or improvement in the joint-pain VAS score. 15 PASI score is a subjective assessment based on estimation by clinicians. Studies have shown that it can be unreliable due to its complex score calculation, it can be difficult to interpret due to its non-linearity and the amount of improvement in the score does not always correspond to clinical relevance. Furthermore, the PASI score does not take into account the disproportionate disease burden reflected in the more visible (hands, feet, nails, face) or covered (genitalia and perianal) body regions, or the impact on patient QoL. PASI responsiveness is weak when patients reach < 10% BSA in any body area because changes in the PASI entirely depend on plaque severity score improvement and may underestimate the general degree of improvement. PASI assessment gets more reliable by experience. 21 Definition for 'clinically meaningful success' is still problematic in psoriasis. The current consensus for clinically meaningful improvement in psoriatic patients is at least 50-75% improvement in disease, which has been translated into 50-75% improvement in the PASI score. 22 In Mayser's study, although there was a statistically significant improvement of PASI in the intervention group, they did not reach 50% improvement in the PASI score to be declared as clinically meaningful improvement. However, in that study, patients' VAS did significantly improve, thus again indicating PASI should not be the only assessment tool for improvement. In Guida's study intervention group, the statistically significant PASI score improvement did reach 50%; however, there was a greater VAS improvement in the control group than in the intervention group. Therefore, just by comparing n-3 PUFA, n-6 PUFA and medication (anti-tumor necrosis factor [TNF]) in both studies, from an aesthetic point of view, n-3 PUFA might improve patients' skin lesions the most as redness, thickness, scale and affected area are the elements of PASI; while medication (anti-TNF) improves patients' VAS the most. We were uncertain how much of the selection and performance bias in Guida's study contributed to these outcomes because either the control group or the intervention group should feel an improvement in both PASI and VAS score simultaneously.
To conclude, these results imply inconclusive effects of n-3 PUFAs on other outcome measures even with statistically significant improvements in the PASI score. Feldman and Krueger 21 recommended the use of the PASI, PGA and QoL measures together to provide a complementary set of measures for studies of moderate to severe psoriasis. The target lesion severity score supplemented by PGA and QoL measures is another approach for patients with a PASI score of < 3. We concur with Feldman and Krueger's suggestion that a standardized assessment tool should be developed.
We investigated each study individually and noticed biases in some studies that may have contributed to the differences in outcomes. Guida et al. 12 reported improved PASI scores. However, they did not perform allocation concealment or blind the participants, which may have affected the positive outcomes. The differences in the outcomes might have also been caused by the different study durations and treatment doses. For example, Guida et al. 12 had a study duration of 6 months using foods naturally rich in n-3 PUFAs (average amount of 2.5 g/day). In contrast, Mayser et al. 16 had a study duration of 6 weeks using intravenous infusion of a high-dose n-3 emulsion (4.2 g EPA, 4.4 g DHA). Furthermore, Strong and Hamill 18 had a study duration of 26 weeks, but the intervention group only received a relatively low dose of fish oil (0.2 g EPA, 0.2 g DHA). Most of the studies either used EPA or combined with DHA, but only Gupta et al. 4, 5 included UVB treatment after EPA and DHA being administered. His first study in 1989 reported that UVB potentiates fish oil's effect while his second study in 1990 reported fish oil treatment was ineffective after cessation of topical corticosteroid. Therefore we remained conservative on the findings of Gupta's study because it raises the question whether n-3 PUFA helps decreasing the affected area without UVB treatment or topical corticosteroid.
Regardless of the contradictory effects of n-3 PUFA treatment for psoriasis, some studies did show an increase in 5-lipoxygenase metabolites (e.g., LTB5) 11 and a significant decrease in LTB4 production. 6 In a recent randomized controlled trial 23 involving 54 rheumatoid arthritis (RA) and six psoriatic arthritis patients who received 12 weeks treatment with n-3 PUFA, they analyzed the proportion of EPA and DHA being incorporated into the erythrocyte membranes. They have concluded that n-3 PUFA resulted in an increased incorporation of the eicosanoid precursor fatty acids (EPA, DHA) in plasma lipids and cell membranes, which had a positive correlation with a significant reduction of disease activity parameters (Disease Activity Score of 28 joints, VAS scale) in RA. AA concentration was found to be decreased in plasma lipids and cell membranes as well. These changes in fatty acid distribution are indicative of a reduction in the production of inflammatory eicosanoids from AA.
Other studies that were conducted in an RA population also concluded that EPA and DHA supplementation can lead to a decline in AA and decreased LTB4 production. Kremer et al. 24 revealed reduction of neutrophil LTB4 in the patients receiving fish oil, while Sperling et al. 25 found a decline of AA and LTB4 with a simultaneous increase in EPA. Therefore presumably n-PUFA could have the same effect on psoriasis patients.
Furthermore, n-3 PUFAs exert cardioprotective effects from reductions in platelet aggregation, blood viscosity, thrombotic tendency, serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol. 5 Weight loss and decreased waist circumference may contribute to decreased severity of psoriasis among obese patients because a chronic low-grade inflammatory state is associated with adiposity. 12 
Strength and limitations
The strength of our study is the inclusion of randomized controlled trials and prospective observational studies. However, there are some limitations in our review. First, there is a potential confounder from intervention in the Guida et al. study. 12 Participants in the intervention group in that study received a diet enriched with n-3 PUFA and an energy-restricted diet. Therefore, interpretation of results from this study should be made with caution. Second, it is unclear how a reliable diagnosis of psoriasis was reached in various studies. Only two studies 12,15 mentioned diagnostic criteria for psoriasis.
CONCLUSIONS
It is inconclusive whether treatment with n-3 PUFAs is associated with improved severity in patients with psoriasis when measured by PASI scores compared with controls. An improvement in the PASI score does not necessarily represent an improvement in the other outcome measures of psoriasis. A widely accepted standardized assessment tool for psoriasis should be established for future clinical trials. Further investigation of n-3 PUFAs is warranted to provide more conclusive evidence of their effect, specifically studies that show the effects of longer-duration, higher-dose n-3 PUFAs on psoriasis with the PASI score or other assessment tools as the primary endpoint.
